JPMorgan resumed coverage of MBX Biosciences with an Overweight rating. The investment bank established a price target of $88 per share.
Analyst Jessica Fye identified the company’s obesity pipeline as a primary driver for the favorable outlook. MBX leverages its proprietary Precision Endocrine Peptide (PEP) platform to develop improved therapies for endocrine and metabolic diseases.
Key clinical data is anticipated in the fourth quarter of 2026. This upcoming release draws significant investor attention to the company's clinical progress.